Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients With Parkinson's Disease.

NCT00226460 Phase 2 COMPLETED

The purpose of this study was to evaluate the differences in safety and efficacy between Parkinson's disease patients who either received transplantation of fetal porcine cells or placebo treatment.

Details

Lead sponsor	Genzyme, a Sanofi Company
Phase	Phase 2
Status	COMPLETED
Start date	1997-08
Completion	2001-01

Conditions

• Parkinson's Disease

Interventions

• Fetal porcine cells, Neurocell-PD

Primary outcomes

• change in UPDRS

Countries

United States